MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings

J. L. Piñana, D. Valcárcel, F. Fernández-Avilés, R. Martino, M. Rovira, P. Barba, C. Martínez, S. Brunet, A. Sureda, E. Carreras, J. Sierra

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)

Abstract

Mycophenolate mofetil (MMF) in combination with CsA seems to lead to earlier post transplant hematological recovery and less mucositis than MTX, with a similar incidence of GVHD. In this study we analyzed the post transplant outcomes of two cohorts of patients who underwent an HLA-identical sibling reduced intensity conditioning transplantation (allo-RIC) with GVHD prophylaxis consisting of CsA in combination with either MMF or a short course of MTX. We included 145 consecutive allo-RIC transplants performed between April 2000 and August 2007. The median follow-up for survivors was 41 months (4-105 months). The study group included 91 males. Median age was 55 years (range 18-71 years). Diagnoses included myeloid (n=65) and lymphoid (n=80) malignancies. GVHD prophylaxis consisted of CsA/MMF in 52 and CsA/MTX in 93 patients. The conditioning regimen was based on fludarabine in combination with BU (n=59) or melphalan (n=86). The occurrence of grade 2-4 mucositis was higher in the CsA/MTX group than in the CsA/MMF group (57 vs 23%, P=0.001). The cumulative incidence of acute and chronic GVHD was similar, 48 vs 50% and 71 vs 68%, respectively (P>0.7). The 2-year relapse and OS were similar in the CsA/MTX and CsA/MMF groups (29 vs 21%, P=0.3 and 52 vs 51%, P=0.7, respectively). Our results support further prospective studies comparing the use of the CsA/MMF combination with CsA/MTX as GVHD prophylaxis in HLA-identical sibling donor allo-RIC recipients. © 2010 Macmillan Publishers Limited All rights reserved.
Original languageEnglish
Pages (from-to)1449-1456
JournalBone Marrow Transplantation
Volume45
DOIs
Publication statusPublished - 1 Sep 2010

Keywords

  • GVHD prophylaxis
  • MTX
  • allo-RIC
  • allo-SCT
  • mycophenolate mofetil
  • reduced-intensity conditioning

Fingerprint

Dive into the research topics of 'MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings'. Together they form a unique fingerprint.

Cite this